Catalyst Brief

← Calendar

Readoutin 135d

MediciNova — MN-166

Phase 3 primary completion: Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS.

Date
Apr 2027
Type
Readout
Indication
Amyotrophic Lateral Sclerosis

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.